Fiessinger J N, Aiach M, Vayssairat M, Juillet Y, Cormier J M, Housset E
Ann Anesthesiol Fr. 1978;19(8):739-45.
Systemic streptokinase has shown its effectiveness in the treatment of recent arterial obstruction of the limbs. The haemorrhagic and embolic complications of this type of treatment nevertheless limit its indications. Streptokinase should be reserved for acute thromboses present for less than two months, and responsible for severe ischaemia without the possibility of surgical treatment. The intra-arterial administration of urokinase limits the risks of systemic fibrinolysis, though the effectiveness of the therapeutic protocols proposed has yet to be demonstrated.
全身性链激酶已显示出对近期肢体动脉阻塞的治疗效果。然而,这类治疗的出血和栓塞并发症限制了其应用指征。链激酶应仅用于病程少于两个月的急性血栓形成,且导致严重缺血而无法进行手术治疗的情况。动脉内注射尿激酶可降低全身性纤维蛋白溶解的风险,不过所提出的治疗方案的有效性尚未得到证实。